---
title: "Weekly Recap | McKesson +6.66%, earnings beat and raised guidance"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/304723306.md"
description: "McKesson gained 6.66% for the week to close at $1,060.84, while the S&P 500 slipped 2.68%, leaving the stock roughly 9.34 percentage points ahead of the benchmark. Trading was quiet on Monday and Tuesday around $995, before volume picked up on Wednesday and the stock broke above $1,000. Thursday saw an intraday high of $1,121.50 followed by a pullback, and Friday settled into a range between $1,046.70 and $1,070.15. The overall pattern was a push higher, a fade, then stabilisation."
datetime: "2026-11-07T08:23:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/304723306.md)
  - [en](https://longbridge.com/en/news/304723306.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/304723306.md)
generator: "portal-rs"
---

# Weekly Recap | McKesson +6.66%, earnings beat and raised guidance

## The Week

McKesson gained 6.66% for the week to close at $1,060.84, while the S&P 500 slipped 2.68%, leaving the stock roughly 9.34 percentage points ahead of the benchmark. Trading was quiet on Monday and Tuesday around $995, before volume picked up on Wednesday and the stock broke above $1,000. Thursday saw an intraday high of $1,121.50 followed by a pullback, and Friday settled into a range between $1,046.70 and $1,070.15. The overall pattern was a push higher, a fade, then stabilisation.

## Key Events

McKesson’s fiscal 2027 second-quarter earnings anchored the week. After the close on 5 November, the company reported revenue slightly above estimates, helped by increased prescription volumes, and adjusted EPS rose 18% year-on-year to $11.68. The same day it raised its fiscal 2027 adjusted EPS outlook to $45.60-$46.40 and filed an 8-K confirming Q2 revenue of $110.96 billion. The stock initially dropped about 2% in after-hours trading, then climbed nearly 4% intraday on 5 November and hit an intraday record high. An S-8 registration filing during the week was routine equity-compensation-related disclosure. EVP, CIO and CTO Francisco Fraga also reported disposal of roughly $786,940 in common shares.

## Analyst Ratings

McKesson is covered by 16 institutions: 10 rate it buy, 3 rate it overweight, and 3 rate it hold, with none at underweight or sell. The consensus rating is buy, with a consensus target of $1,060.57, essentially flat versus the spot price, implying roughly -0.03% upside. Individual targets range from $845 to $1,260, reflecting wide dispersion. McKesson ranks third among eight covered companies in the medical product distributors industry. During the week, Evercore ISI Group, TD Cowen, and UBS maintained buy or outperform ratings and raised their price targets.

## The Week Ahead

US macro data dominates the coming week. CPI and core CPI are due on 10 November, with prior readings of 3.7% and 2.6%, and consensus sees core CPI at 2.8%; the NFIB small business optimism index arrives the same day. Wholesale sales data hits on 9 November. On the company side, McKesson’s next major disclosure is the fiscal Q3 results on 3 February 2027, slated for after the close.

## In Short

McKesson beat the broader market this week on the back of earnings and raised guidance, touching an all-time high. Broker ratings skew positive, with the consensus target roughly level with the spot price but individual targets spread widely. On the latest trading day, large-lot money was a net seller while small and medium orders were net buyers. Going forward, watch whether macro inflation prints disturb valuation expectations, and whether prescription-volume growth carries into the next earnings round.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [MCK.US](https://longbridge.com/en/quote/MCK.US.md)

## Related News & Research

- [McKesson Raises Fiscal 2027 Adjusted EPS Outlook to $45.60-$46.40](https://longbridge.com/en/news/304346911.md)
- [McKesson Q2 revenue slightly beats estimates, helped by increased prescription volumes](https://longbridge.com/en/news/304335925.md)
- [Option Care Health Q3 GAAP diluted EPS rises 19% to $0.38](https://longbridge.com/en/news/304270150.md)
- [The S&P 500 is shrugging off Nvidia's selloff. Here's what's keeping the rest of the market afloat.](https://longbridge.com/en/news/305355417.md)
- [Nvidia options traders bank on longer-term stock recovery](https://longbridge.com/en/news/305359219.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**